What Happened
On October 15, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use, known as the CHMP, adopted a positive opinion recommending EU marketing authorization for orforglipron, which carries the brand name Foundayo. At the time of the announcement, the European Commission's final decision was still pending.
The CHMP opinion is the central scientific step in the EU process. It does not by itself grant authorization, but a positive recommendation is typically followed by a formal Commission decision.
What Orforglipron Is
Orforglipron is a small-molecule GLP-1 receptor agonist. This is an important distinction. Unlike semaglutide and most other GLP-1 drugs, which are peptides, orforglipron is a small molecule. That difference shapes both how it is manufactured and how it is taken.
It is taken orally. Because it is a small molecule rather than a peptide, it does not require the strict fasting-and-water protocol that oral semaglutide, a peptide, depends on for absorption. Orforglipron can be dosed flexibly at any time of day.
The Regulatory Path So Far
Orforglipron already has a track record with other regulators. It was approved by the US Food and Drug Administration in April 2026 and authorized in the United Kingdom by the MHRA in August 2026. The positive CHMP opinion in October 2026 adds the European Union's scientific endorsement to that list, pending the Commission's final word.
Why the Small-Molecule Design Matters
Being a small molecule gives orforglipron practical advantages over injectable peptides. Small molecules are generally easier and cheaper to manufacture and scale, which can ease supply constraints that have affected injectable peptide drugs. The oral, any-time dosing also removes the handling and timing hurdles associated with injections and with the rigid protocol oral peptides require.
Why It Matters
If the European Commission follows the CHMP recommendation, orforglipron would join the growing set of GLP-1 options available across major markets. Its small-molecule, oral format positions it differently from the injectable peptides that have dominated the category, and manufacturing scalability is one reason the drug has drawn close attention.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.